Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.51 |
| ▸ | GSK3B | P49841 | 10/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22664697 | 1.00 | EPHX2 (0.51) | EPHX2GSK3BMAPK14KDRCYP3A4 | |
| SCHEMBL29533531 | 0.87 | GSK3B (0.48) | GSK3BMAPK14ABL1PIK3C3MAPK8 | |
| SCHEMBL22660077 | 0.87 | GSK3B (0.48) | GSK3BMAPK14ABL1PIK3C3MAPK8 | |
| SCHEMBL22664601 | 0.87 | GSK3B (0.47) | GSK3BKDRCYP3A4AAK1PIK3C3 | |
| SCHEMBL29533456 | 0.87 | GSK3B (0.47) | GSK3BKDRCYP3A4AAK1PIK3C3 | |
| SCHEMBL22659485 | 0.86 | GSK3B (0.51) | GSK3BMAPK14ABL1PIK3C3MAPT | |
| SCHEMBL22664898 | 0.85 | GSK3B (0.54) | GSK3BMAPK14ABL1PIK3C3MAPT | |
| SCHEMBL29533370 | 0.83 | GSK3B (0.45) | GSK3BMAPK14PIK3C3MAPK8MAPK10 | |
| SCHEMBL22664857 | 0.83 | GSK3B (0.45) | GSK3BMAPK14PIK3C3MAPK8MAPK10 | |
| SCHEMBL22664629 | 0.82 | PIK3C3 (0.45) | GSK3BMAPK14PIK3C3MAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20220259194-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2022-08-18 | — | — | US | disclosed |
| EP-3969124-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | EPHX2 3431/4885GSK3B 318/4885MAPK14 266/4885 |
| US-20220259194-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | EPHX2 3431/4885GSK3B 318/4885MAPK14 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.